Table 1.
Baseline characteristics of the Brugada syndrome cohort.
| Characteristic | Overall (n = 550) | Adult (n = 505) | Paediatric/Young (n = 45) | P-value |
|---|---|---|---|---|
| Demographics and clinical presentation | ||||
| Female | 40 (7.27) | 34 (6.73) | 6 (13.3) | 0.126 |
| Onset age | 51 ± 23 | 52 ± 19 | 21 ± 5 | - |
| Current age | 58 ± 23 | 60 ± 19 | 27 ± 9 | - |
| Initial type 1 BrP | 341 (62.0) | 312 (61.8) | 29 (64.4) | 0.631 |
| Type 1 BrP | 413 (75.1) | 381 (75.4) | 31 (71.1) | 0.716 |
| Evolution of BrP type | 188 (34.2) | 171 (33.9) | 17 (37.8) | 0.513 |
| Fever | 87 (15.8) | 74 (14.7) | 13 (28.9) | 0.018 |
| Family history of BrS | 17 (3.09) | 12 (2.38) | 5 (11.1) | 0.009 |
| Family history of SCD | 45 (8.18) | 40 (7.92) | 5 (11.1) | 0.401 |
| Syncope | 237 (43.1) | 213 (42.2) | 24 (53.3) | 0.160 |
| Syncope frequency | 1.49 ± 16.4 | 1.54 ± 17.1 | 0.933 ± 1.19 | 0.162 |
| VT/VF | 86 (15.6) | 77 (15.2) | 9 (20.0) | 0.394 |
| Sustained VT/VF frequency | 0.77 ± 4.16 | 0.80 ± 4.33 | 0.42 ± 1.01 | 0.294 |
| Initial asymptomatic | 332 (60.4) | 312 (61.8) | 20 (44.4) | 0.026 |
| Initial symptomatic | 218 (39.6) | 193 (38.2) | 25 (55.5) | 0.023 |
| Initial syncope | 175 (31.8) | 154 (30.5) | 21 (46.7) | 0.030 |
| Initial VT/VF | 43 (7.82) | 39 (7.72) | 4 (8.89) | 0.771 |
| Initial diagnostic evaluation | ||||
| Flecainide challenge | 234 (42.5) | 209 (41.4) | 25 (55.6) | 0.083 |
| Positive flecainide challenge | 204 (87.2) | 185 (88.5) | 19 (76.0) | 0.114 |
| EPS | 112 (20.4) | 108 (21.4) | 4 (8.89) | 0.052 |
| Positive EPS | 76 (67.9) | 74 (68.5) | 2 (50.0) | 0.596 |
| Holter study | 153 (27.8) | 139 (27.5) | 14 (31.1) | 0.605 |
| Arrhythmia in Holter Study | 64 (41.8) | 62 (44.6) | 2 (14.3) | 0.048 |
| Other arrhythmias | 81 (14.7) | 79 (15.6) | 2 (4.44) | 0.046 |
| Genetic test | 53 (9.64) | 45 (8.91) | 8 (17.8) | 0.064 |
| Positive genetic test | 18 (34.0) | 13 (28.9) | 5 (62.5) | 0.104 |
| Echocardiogram | 259 (47.1) | 236 (46.7) | 23 (51.1) | 0.641 |
| EEG | 61 (11.1) | 55 (10.9) | 6 (13.3) | 0.619 |
| Positive EEG | 16 (26.2) | 16 (29.1) | 0 (0.00) | 0.325 |
| Treatment and outcomes | ||||
| ICD | 143 (26.0) | 135 (26.7) | 8 (17.8) | 0.218 |
| Death | 39 (7.09) | 38 (7.52) | 1 (2.22) | 0.356 |
| BrS death | 6 (1.09) | 5 (0.99) | 1 (2.22) | 1.00 |
| Follow-up duration | 83 ± 80 | 83 ± 80 | 73 ± 83 | 0.314 |
| Baseline ECG characteristics | ||||
| Heart rate | 79 ± 26 | 78 ± 26 | 86 ± 26.5 | 0.018 |
| P-wave duration | 113 ± 17 | 113 ± 16 | 108 ± 15.8 | 0.160 |
| PR interval | 166 ± 31 | 166 ± 32 | 158 ± 30 | 0.022 |
| QRS interval | 103 ± 16 | 104 ± 16 | 103 ± 17.3 | 0.883 |
| QT interval | 368 ± 48.0 | 369 ± 48.0 | 355 ± 48.5 | 0.004 |
| QTc interval | 415 ± 35.0 | 415 ± 34.5 | 410 ± 43.8 | 0.172 |
| P axis | 64 ± 24 | 64 ± 24 | 60 ± 23 | 0.508 |
| QRS axis | 60 ± 47 | 58 ± 47 | 75 ± 39 | 0.017 |
| T axis | 56 ± 28.0 | 56 ± 27.3 | 57.5 ± 30.3 | 0.617 |
| V5 R wave amplitude | 1.42 ± 0.76 | 1.42 ± 0.77 | 1.25 ± 0.60 | 0.139 |
| V1 S wave amplitude | 0.54 ± 0.44 | 0.54 ± 0.439 | 0.49 ± 0.98 | 0.614 |
| 1st degree AV block | 55 (10.0) | 52 (10.3) | 3 (6.67) | 0.602 |
| Interventricular delay | 149 (27.1) | 138 (27.3) | 11 (24.4) | 0.856 |
For discrete variables, the table presents the number of patients (patient percentage concerning the cohort or subgroup). Bold text indicates P < 0.05.